These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38029547)

  • 41. IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER.
    Zanatto RM; Santos G; Oliveira JC; Pracucho EM; Nunes AJF; Lopes-Filho GJ; Saad SS
    Arq Bras Cir Dig; 2020; 33(3):e1524. PubMed ID: 33331426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
    Gao J; Sun ZW; Li YY; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
    E J; Xing J; Gong H; He J; Zhang W
    Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
    Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
    Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
    Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
    Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    van 't Erve I; Wesdorp NJ; Medina JE; Ferreira L; Leal A; Huiskens J; Bolhuis K; van Waesberghe JTM; Swijnenburg RJ; van den Broek D; Velculescu VE; Kazemier G; Punt CJA; Meijer GA; Fijneman RJA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34820593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
    Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.
    Segelov E; Thavaneswaran S; Waring PM; Desai J; Robledo KP; Gebski VJ; Elez E; Nott LM; Karapetis CS; Lunke S; Chantrill LA; Pavlakis N; Khasraw M; Underhill C; Ciardiello F; Jefford M; Wasan H; Haydon A; Price TJ; van Hazel G; Wilson K; Simes J; Shapiro JD
    J Clin Oncol; 2016 Jul; 34(19):2258-64. PubMed ID: 27114605
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?
    Yokota T
    Anticancer Agents Med Chem; 2012 Feb; 12(2):163-71. PubMed ID: 22043994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
    Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients.
    Li Y; Monzo M; Moreno I; Martinez-Rodenas F; Hernandez R; Castellano JJ; Canals J; Han B; Muñoz C; Navarro A
    Int J Colorectal Dis; 2020 May; 35(5):805-813. PubMed ID: 32088737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRAS
    Kennedy SA; Jarboui MA; Srihari S; Raso C; Bryan K; Dernayka L; Charitou T; Bernal-Llinares M; Herrera-Montavez C; Krstic A; Matallanas D; Kotlyar M; Jurisica I; Curak J; Wong V; Stagljar I; LeBihan T; Imrie L; Pillai P; Lynn MA; Fasterius E; Al-Khalili Szigyarto C; Breen J; Kiel C; Serrano L; Rauch N; Rukhlenko O; Kholodenko BN; Iglesias-Martinez LF; Ryan CJ; Pilkington R; Cammareri P; Sansom O; Shave S; Auer M; Horn N; Klose F; Ueffing M; Boldt K; Lynn DJ; Kolch W
    Nat Commun; 2020 Jan; 11(1):499. PubMed ID: 31980649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.
    Conti A; Majorini MT; Elliott R; Ashworth A; Lord CJ; Cancelliere C; Bardelli A; Seneci P; Walczak H; Delia D; Lecis D
    Oncotarget; 2015 May; 6(13):10994-1008. PubMed ID: 26028667
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines.
    Khan S; Cameron S; Blaschke M; Moriconi F; Naz N; Amanzada A; Ramadori G; Malik IA
    World J Gastroenterol; 2014 Mar; 20(11):2979-94. PubMed ID: 24659889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
    Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
    PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Double
    Deshwar A; Margonis GA; Andreatos N; Barbon C; Wang J; Buettner S; Wagner D; Sasaki K; Beer A; Løes IM; Pikoulis E; Damaskos C; Garmpis N; Kamphues K; He J; Kaczirek K; Poultsides G; Lønning PE; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    Anticancer Res; 2018 May; 38(5):2891-2895. PubMed ID: 29715113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.
    Valentino JD; Elliott VA; Zaytseva YY; Rychahou PG; Mustain WC; Wang C; Gao T; Evers BM
    Surgery; 2012 Aug; 152(2):277-85. PubMed ID: 22828149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.